AN2 Therapeutics, Inc. Operating Expenses
AN2 Therapeutics, Inc. (ANTX) reported Operating Expenses of $8.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- AN2 Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $8.90M, a 23.39% increase year-over-year.
- AN2 Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $10.55M, a 8.55% decline year-over-year.
- AN2 Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $9.32M, a 8.35% increase year-over-year.
- AN2 Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $10.04M, a 28.36% decline year-over-year.
- AN2 Therapeutics, Inc. operating expenses for fiscal 2025 was $38.11M, a 32.89% decline from fiscal 2024.
- AN2 Therapeutics, Inc. operating expenses for fiscal 2024 was $56.79M, a 18.45% decline from fiscal 2023.
- AN2 Therapeutics, Inc. operating expenses for fiscal 2023 was $69.64M, a 64.77% increase from fiscal 2022.
- AN2 Therapeutics, Inc. operating expenses for fiscal 2022 was $42.26M, a 95.89% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.90M 10-Q · filed 2026-08-11 | $19.45M 10-Q · filed 2026-08-11 | $28.77M derived: sum of 3 quarters · filed 2026-08-11 | $38.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $10.55M 10-Q · filed 2026-05-11 | $19.87M derived: sum of 2 quarters · filed 2026-05-11 | $29.91M derived: sum of 3 quarters · filed 2026-05-11 | $37.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $9.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $19.36M derived: sum of 2 quarters · filed 2026-03-17 | $26.57M derived: sum of 3 quarters · filed 2026-08-11 | $38.11M 10-K · filed 2026-03-17 |
| 2025-09-30 | $10.04M 10-Q · filed 2025-11-12 | $17.26M derived: sum of 2 quarters · filed 2026-08-11 | $28.79M 10-Q · filed 2025-11-12 | $37.39M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $7.22M 10-Q · filed 2026-08-11 | $18.75M 10-Q · filed 2026-08-11 | $27.35M derived: sum of 3 quarters · filed 2026-08-11 | $41.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $11.54M 10-Q · filed 2026-05-11 | $20.14M derived: sum of 2 quarters · filed 2026-05-11 | $34.15M derived: sum of 3 quarters · filed 2026-05-11 | $50.03M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $8.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $22.61M derived: sum of 2 quarters · filed 2026-03-17 | $38.49M derived: sum of 3 quarters · filed 2026-03-17 | $56.79M 10-K · filed 2026-03-17 |
| 2024-09-30 | $14.01M 10-Q · filed 2025-11-12 | $29.89M derived: sum of 2 quarters · filed 2025-11-12 | $48.19M 10-Q · filed 2025-11-12 | $67.00M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $15.88M 10-Q · filed 2025-08-12 | $34.18M 10-Q · filed 2025-08-12 | $52.99M derived: sum of 3 quarters · filed 2025-08-12 | $71.17M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $18.30M 10-Q · filed 2025-05-13 | $37.11M derived: sum of 2 quarters · filed 2025-05-13 | $55.29M derived: sum of 3 quarters · filed 2025-05-13 | $71.89M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $18.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $36.99M derived: sum of 2 quarters · filed 2025-03-25 | $53.60M derived: sum of 3 quarters · filed 2025-03-25 | $69.64M 10-K · filed 2025-03-25 |
| 2023-09-30 | $18.18M 10-Q · filed 2024-11-13 | $34.78M derived: sum of 2 quarters · filed 2024-11-13 | $50.82M 10-Q · filed 2024-11-13 | $63.30M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $16.60M 10-Q · filed 2024-08-13 | $32.64M 10-Q · filed 2024-08-13 | $45.12M derived: sum of 3 quarters · filed 2024-08-13 | $56.89M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $16.04M 10-Q · filed 2024-05-14 | $28.52M derived: sum of 2 quarters · filed 2024-05-14 | $40.28M derived: sum of 3 quarters · filed 2024-05-14 | $50.62M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $12.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $24.25M derived: sum of 2 quarters · filed 2024-03-29 | $34.58M derived: sum of 3 quarters · filed 2024-03-29 | $42.26M 10-K · filed 2024-03-29 |
| 2022-09-30 | $11.77M 10-Q · filed 2023-11-09 | $22.10M derived: sum of 2 quarters · filed 2023-11-09 | $29.79M 10-Q · filed 2023-11-09 | $37.38M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $10.33M 10-Q · filed 2023-08-10 | $18.02M 10-Q · filed 2023-08-10 | $25.61M derived: sum of 3 quarters · filed 2023-08-10 | $32.54M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $7.68M 10-Q · filed 2023-05-11 | $15.28M derived: sum of 2 quarters · filed 2023-05-11 | $22.21M derived: sum of 3 quarters · filed 2023-05-11 | $27.21M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $14.53M derived: sum of 2 quarters · filed 2023-03-29 | $19.52M derived: sum of 3 quarters · filed 2023-03-29 | $21.57M 10-K · filed 2023-03-29 |
| 2021-09-30 | $6.93M 10-Q · filed 2022-11-09 | $11.93M derived: sum of 2 quarters · filed 2022-11-09 | $13.98M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $5.00M 10-Q · filed 2022-08-11 | $7.05M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $2.05M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |